Carcinoma of prostate: Case against immediate hormonal therapy

Prostate

Volumn 28, Issue 3, 1996, Pages 205-208

  Smith, Philip H ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; HUMAN; MALE; METASTASIS; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 0030095217     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199603)28:3<205::AID-PROS8>3.0.CO;2-D     Document Type: Article

References (22)

1. Ferguson JD: Cancer of the prostate II. BMJ 4:512-514, 1970.
2. Veterans Administration Cooperative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011-1017, 1967.
3. Prostate Cancer Trialists Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 346:265-269, 1995.
4. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379-385, 1993.
5. Coffey DS: Prostate cancer. An overview of an increasing dilemma. Cancer 71(suppl):880-886, 1993.
6. Walsh PC, Mostwin JL: Radical prostatectomy and cysto-prostatectomy with preservation of potency: Results of a new nerve sparing technique. Br J Urol 56: 694-697, 1984.
7. Pearson JD, Carter HB: Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 152:1743-1748, 1994.
8. Andriole GL, Catalona WJ: Using PSA to screen for prostate cancer. Urol Clin North Am 20:647-651, 1993.
9. Partin AW, Pound CR, Clemens JQ: Serum PSA after anatomic radical prostatectomy. Urol Clin North Am 20:713-725, 1993.
10. Smith JA: Management in localized prostate cancer. In Proceedings of International Workshop on Prostate Cancer and Benign Hypertrophy, October 26-30, 1991, Sea Island, Georgia.
11. Zincke H: Combined surgery and immediate adjuvant hormonal treatment for stage D1 adenocarcinoma of the prostate. Mayo Clinic experience. Semin Urol 8:175-183, 1990.
12. Madsen PO, Graversen PH, Gasser TC, Corle DK: Treatment of localized prostatic cancer. Radical prostatectomy versus placebo. A 15-year follow up. Scand J Urol Nephrol Suppl 110:95-100, 1988.
13. Schmidt JD, Gibbons RP, Murphy GP, Bartolucci A. Adjuvant therapy for localized prostate cancer. Cancer 71(suppl):1005-1013, 1993.
14. Adolfsson J, Rünström L, Löwhagen T, Carstensen J, Hedlund PO: Deferred treatment of clinically low grade prostate cancer: The experience from a prospective series at the Karolinska Hospital. J Urol 152:1757-1760, 1994.
15. Johansson JE: Expectant management of early stage prostatic cancer: Swedish experience. J Urol 152:1753-1756, 1994.
16. Chodak GW: The role of watchful waiting in the management of localized prostate cancer. J Urol 152:1766-1768, 1994.
17. Warner J, Whitmore WF Jr: Expectant management of clinically localized prostate cancer. J Urol 152:1761-1765, 1994.
18. Eisen M, Nappe HE, Vock R: Thombocytere-aggrega-tionshemming bei oestrogen-behadelten prostata-carcinoma-patients. Urologe A14:132-136, 1974.
19. Akakura K, Bruchovwky N, Goldenberg SC, Rennie PS, Buckley AR, Sullivan LD: Effects of intermittent androgen suppression on androgen-dependent tumours. Cancer 71:2782-2789, 1993.
20. Crawford ED, Eisenberger MA, McLeod DG, et al: A comparison of leuprolide with and without flutamide in previously untreated patients with disseminated prostate carcinoma: a placebo controlled study. N Engl J Med 321:419-424, 1989.
21. Denis LJ, Whelan P, Carneiro De Moura JL, et al: Goserelin acetate and flutamide versus bilateral orchidectomy: A phase III EORTC trial (30853). Urology 42:119-129, 1993.
22. Smith PH: Hormone therapy: An overview. Cancer Surv 23:171-181, 1995.